Mithradote Bio is focused on developing a groundbreaking medication aimed at preventing drug-facilitated sexual assault, specifically targeting "date-rape" drugs. Their lead product, M-101, is a novel sublingual pan-antidote designed to counteract the effects of benzodiazepines, commonly known as "roofies," as well as other GABA agonists. This innovative formulation allows for rapid absorption, ensuring that the antidote acts quickly after administration, which is crucial in emergency situations. The sublingual delivery method also enhances convenience, making it easy for individuals to carry the medication for immediate use if necessary.

The company emphasizes the importance of accessibility and self-administration in their product design, positioning M-101 as the first self-administered antidote specifically targeting these types of drugs. By providing a fast-acting solution, Mithradote Bio aims to empower individuals and enhance safety in situations where drug-facilitated assaults may occur. Their commitment to addressing this critical issue highlights the potential impact of their technology in promoting personal safety and well-being.

United States

Mithradote Bio is a biotechnology company developing a novel medication to help prevent drug-facilitated sexual assault

Mithradote Bio

Company Details